Description

PHAGE GP 2 TABLET is a dual-action oral antidiabetic medicine containing Glimepiride 2 mg and Metformin Hydrochloride (usually 500 mg or 1000 mg, depending on formulation type). It is used for the effective management of Type 2 Diabetes Mellitus, particularly in patients who require combination therapy to achieve glycemic targets.

• Glimepiride is a sulfonylurea that stimulates the pancreas to release more insulin, especially in response to meals.

• Metformin is a biguanide that decreases liver glucose production and enhances insulin sensitivity in muscles and fat.

• Fasting blood glucose

• Postprandial (after-meal) glucose levels

• HbA1c (long-term glucose indicator)

• Type 2 Diabetes Mellitus not controlled by monotherapy

• Second-line or first-line combination therapy in adults

• Long-term glycemic regulation with dual benefits

• Higher Glimepiride dose (2 mg) for patients needing stronger insulin stimulation

• Effective dual mechanism to target insulin secretion and resistance

• Reduces the need for multiple tablets and improves treatment adherence

• Often associated with improved metabolic markers and reduced diabetic complications

• May promote mild weight control in some patients due to Metformin’s action